Actively Recruiting
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Led by University of Texas at Austin · Updated on 2026-05-01
50
Participants Needed
1
Research Sites
197 weeks
Total Duration
On this page
Sponsors
U
University of Texas at Austin
Lead Sponsor
L
Lehigh University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
CONDITIONS
Official Title
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- English as primary language, and comprehension suitable to understand experimenter instructions
- Meet criteria for a current major depressive episode diagnosed through the Structured Clinical Interview for DSM-5 (SCID-5)
- Early onset of depression (before age 30) with either a current episode lasting more than 2 years or at least two lifetime major depressive episodes
- Quick Inventory of Depression Symptomology Self-Report (QIDS) score greater than 14 at baseline and prior to first sertraline dose
- Willing and able to undergo MRI and EEG procedures
You will not qualify if you...
- Non-early onset or non-chronic major depressive disorder
- Failure to respond to prior adequate antidepressant treatment during current episode
- Currently pregnant, planning pregnancy, or breastfeeding
- History or current psychosis or bipolar disorder
- Moderate or greater substance-use disorder in past 6 months
- Unstable psychiatric or medical conditions requiring hospitalization or contraindicating study medication
- Contraindications to MRI including unsafe implants or brain conditions
- History of epilepsy, significant brain injury, brain surgery, or anticonvulsant use
- Treatment with electroconvulsive therapy, vagus nerve stimulation, or transcranial magnetic stimulation during current episode
- Use of medications that interfere with study medication, including antipsychotics and mood stabilizers
- Current regular depression-specific evidence-based psychotherapy
- Considered a significant suicide risk by study investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600
Austin, Texas, United States, 78712
Actively Recruiting
Research Team
G
Greg Fonzo, Ph.D.
CONTACT
L
Lauren Enten, B.S.A
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here